Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle
Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle
批准号:
10589886
负责人:
Danuta Szczesna-Cordary
金额:
$38.38万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-05 至 2024-03-31
关键词:
ActinsAgeAlanineAlkaliesAmino AcidsBindingBiological AssayCalciumCardiacCardiac Muscle ContractionCardiomyopathiesCellsComplexConsumptionCytoskeletonDataDiseaseEchocardiographyEtiologyEventFilamentFluorescenceFluorescent ProbesFrequenciesGenesGlycineHealthHeartHeart DiseasesHomeostasisHumanHypertrophic CardiomyopathyHypertrophyIn VitroInvestigationLabelLightLinkLysineMeasurementMetabolicMitochondriaModelingModificationMolecularMotorMusMuscleMuscle ContractionMuscle FibersMutateMutationMyocardiumMyosin ATPaseMyosin Alkali Light ChainsN-terminalOrganOrganellesOutputOxidative PhosphorylationPathologicPeroxisome Proliferator-Activated ReceptorsPhenotypePhysiologicalPlayProductionProteinsQuantum DotsRNA SplicingRegulationRelaxationRespirationRespiratory ChainRoleSkeletal MuscleSkinSmooth Muscle MyosinsSystemTestingThick FilamentTransgenic MiceTransgenic OrganismsVariantVentricularWorkcardiac muscle diseasecell motilityhemodynamicshexokinasein vivoinsightmouse modelmutantnovelnovel therapeuticspapillary musclerespiratoryresponsesex
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The scientific premise of this application regards the cardiac specific expression of the long ELC containing
the N-terminal ELC extension (N-ELC) and its physiologically important role in regulating myosin motor function
and force production in muscle. We hypothesize that cardiac N-ELC works as a molecular linker and/or
energetic switch of the actin-myosin interaction by regulating the transition of myosin cross-bridges from a super-
relaxed (SRX) to a disordered-relaxed (DRX) state, and the proportion of myosin heads that are available for the
interaction with actin. In DRX, the myosin heads protrude into the interfilament space but are restricted from
binding to actin, while in the SRX state, the heads are neatly ordered along the thick filament axis but cycle at a
highly inhibited ATP turnover rate. We further hypothesize that hypertrophic cardiomyopathy mutations in
myosin ELC promote the SRX-to-DRX transition and the deletion of the N-ELC counteracts this transition and
stabilizes the energy conservation SRX state. We will test these hypotheses using two mouse models of
hypertrophic HCM-A57G (Alanine57Glycine) and restrictive RCM-E143K (Glutamate143Lysine)
cardiomyopathy. We will also use transgenic Δ43 mice expressing a 43-aa truncated ELC, and double transgenic
mice: A57GxΔ43 and E143KxΔ43, expressing Δ43-ELC in the background of HCM or RCM mutations. The data
will be compared to age and sex matched WT-ELC mice expressing the human ventricular ELC (MYL3 gene).
SPECIFIC AIM 1: DEFINE THE ROLE OF MYOSIN ELC AND ITS N-TERMINUS (N-ELC) IN THE REGULATION
OF MYOSIN MOTOR FUNCTION AND CARDIAC MUSCLE CONTRACTION. This aim will focus on the molecular
triggers of ELC-induced heart remodeling studied at the level of myosin molecules, myofibers and the whole
heart. The N-ELC-dependent regulation of actin-myosin interactions will be studied using: 1) mant-ATP-chase
assays and the proportion of myosin heads in SRX vs. DRX states; 2) Quantum dot-labeled actin±Tm-Tn motility
assays; 3) Skinned and intact muscle fibers and force-pCa as well as force and calcium transient measurements;
and 4) echocardiography and invasive hemodynamics to assess contractile responses of the heart in vivo.
SPECIFIC AIM 2: THE ROLE MYOSIN ELC IN ENERGETIC REMODELING OF THE HEART IN MOUSE MODELS
OF CARDIOMYOPATHY. The analysis of the metabolic landscape in A57G, E143K, Δ43, A57GxΔ43 and
E143KxΔ43 vs. WT hearts will be performed to identify the specific mechanisms that govern energy utilization
in all ELC-mutant vs. WT mice. Mitochondrial function will be assessed by determination of mitochondrial
respiration, enzymatic activity of respiratory complexes as well as ATP production/consumption. Steady-state
levels of candidate proteins implicated in energy production such as Hexokinases I and II, various mitochondrial
respiratory chain subunits (Complexes I to V) as well as peroxisome proliferator-activated receptor coactivator α
(PGC-1α) will be assessed in all models to characterize the broader implications of cardiac muscle disease
resulting from ELC-linked modifications.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3389/fcvm.2022.988066
发表时间:
2022
期刊:
FRONTIERS IN CARDIOVASCULAR MEDICINE
影响因子:
3.6
作者:
[Kazmierczak, Katarzyna, Liang, Jingsheng, Gomez-Guevara, Michelle, Szczesna-Cordary, Danuta]
通讯作者:
Szczesna-Cordary, Danuta
DOI:
10.3390/life13071463
发表时间:
2023-06-28
期刊:
Life (Basel, Switzerland)
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1085/jgp.202012801
发表时间:
2021-07-05
期刊:
The Journal of general physiology
影响因子:
--
作者:
[Sitbon YH, Diaz F, Kazmierczak K, Liang J, Wangpaichitr M, Szczesna-Cordary D]
通讯作者:
Szczesna-Cordary D
DOI:
10.3390/ijms232415589
发表时间:
2022-12-09
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[]
通讯作者:
Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle
-
批准号:10376748
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2020
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
The myosin light chain regulators of heart function
-
批准号:10009818
-
项目类别:
-
资助金额:$48.75万
-
财政年份:2019
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Novel cardioskeletal myopathy associated with MYL2
-
批准号:9272949
-
项目类别:
-
资助金额:$49.88万
-
财政年份:2015
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Myosin ELC, a novel therapeutic target for FHC
-
批准号:8586553
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Myosin ELC, a novel therapeutic target for FHC
-
批准号:8237859
-
项目类别:
-
资助金额:$40.69万
-
财政年份:2011
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Myosin ELC, a novel therapeutic target for FHC
-
批准号:8392246
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2011
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
THE N-TERMINAL MYOSIN-ELC REGULATION OF CARDIAC MUSCLE CONTRACTION
-
批准号:8361291
-
项目类别:
-
资助金额:$0.99万
-
财政年份:2011
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations
-
批准号:7068457
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations.
-
批准号:8242787
-
项目类别:
-
资助金额:$38.39万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations
-
批准号:6897942
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations
-
批准号:6686520
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations.
-
批准号:7784510
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations.
-
批准号:7603103
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations
-
批准号:6765918
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations.
-
批准号:7466172
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Functional Consequences of FHC-linked RLC Mutations.
-
批准号:8041040
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2003
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Cardiac Troponin in Health and Disease
-
批准号:8022884
-
项目类别:
-
资助金额:$38.25万
-
财政年份:1989
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
Training Program in Cardiovascular Signaling
-
批准号:8022900
-
项目类别:
-
资助金额:$28.9万
-
财政年份:1976
-
负责人:Danuta Szczesna-Cordary
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: